Verrica Pharmaceuticals Inc. Increase (Decrease) in Accounts Receivable
Verrica Pharmaceuticals Inc. (VRCA) reported Increase (Decrease) in Accounts Receivable of $5.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-06
- Verrica Pharmaceuticals Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $3.21M, a 10.35% decline year-over-year.
- Verrica Pharmaceuticals Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $2.46M, a 55.68% decline year-over-year.
- Verrica Pharmaceuticals Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$1.79M, a 989.05% decline year-over-year.
- Verrica Pharmaceuticals Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$2.15M.
- Verrica Pharmaceuticals Inc. increase (decrease) in accounts receivable for fiscal 2025 was $5.21M.
- Verrica Pharmaceuticals Inc. increase (decrease) in accounts receivable for fiscal 2024 was -$4.20M, a 208.81% decline from fiscal 2023.
- Verrica Pharmaceuticals Inc. increase (decrease) in accounts receivable for fiscal 2023 was $3.86M.
- Verrica Pharmaceuticals Inc. increase (decrease) in accounts receivable for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $5.68M 10-Q · filed 2026-08-06 | $3.89M derived: sum of 3 quarters · filed 2026-08-06 | $1.75M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.46M 10-Q · filed 2026-05-12 | $677.00K derived: sum of 2 quarters · filed 2026-05-12 | -$1.47M derived: sum of 3 quarters · filed 2026-05-12 | $2.12M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$1.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$3.93M derived: sum of 2 quarters · filed 2026-03-11 | -$347.00K derived: sum of 3 quarters · filed 2026-08-06 | $5.21M 10-K · filed 2026-03-11 |
| 2025-09-30 | -$2.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.44M derived: sum of 2 quarters · filed 2026-08-06 | $7.00M 10-Q · filed 2025-11-14 | $7.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $3.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $9.14M 10-Q · filed 2026-08-06 | $9.35M derived: sum of 3 quarters · filed 2026-08-06 | -$832.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $5.56M 10-Q · filed 2026-05-12 | $5.76M derived: sum of 2 quarters · filed 2026-05-12 | -$4.42M derived: sum of 3 quarters · filed 2026-05-12 | -$1.39M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $201.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$9.98M derived: sum of 2 quarters · filed 2026-03-11 | -$6.95M derived: sum of 3 quarters · filed 2026-03-11 | -$4.20M 10-K · filed 2026-03-11 |
| 2024-09-30 | -$10.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$7.15M derived: sum of 2 quarters · filed 2025-11-14 | -$4.40M 10-Q · filed 2025-11-14 | -$4.49M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $3.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $5.78M 10-Q · filed 2025-08-12 | $5.69M derived: sum of 3 quarters · filed 2025-08-12 | $9.64M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $2.75M 10-Q · filed 2025-05-13 | $2.67M derived: sum of 2 quarters · filed 2025-05-13 | $6.61M derived: sum of 3 quarters · filed 2025-05-13 | $6.61M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$86.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $3.86M derived: sum of 2 quarters · filed 2025-03-11 | $3.86M derived: sum of 3 quarters · filed 2025-03-11 | $3.86M 10-K · filed 2025-03-11 |
| 2023-09-30 | $3.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $3.95M derived: sum of 2 quarters · filed 2024-11-05 | $3.95M 10-Q · filed 2024-11-05 | $3.95M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | $0.00 derived: sum of 3 quarters · filed 2024-08-14 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-13 | $0.00 derived: sum of 2 quarters · filed 2024-05-13 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 10-K · filed 2024-02-29 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |